1 / 1

Enbrel(Etanercept)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Formulation:

INJECTION

Validity period:

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Enbrel (etanercept) is a biologic TNF inhibitor used to treat chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It functions by binding to TNF-α and TNF-β, blocking their interaction with cell surface receptors, thereby reducing inflammation and disease progression. Enbrel is administered subcutaneously and is available in multiple formulations, including prefilled syringes and autoinjectors.

Key safety considerations include an increased risk of serious infections, malignancies, and hypersensitivity reactions. Patients must be screened for latent tuberculosis and monitored for infections during therapy. Enbrel is contraindicated in sepsis and requires careful consideration in patients with heart failure, demyelinating disorders, or hepatitis B infection.

Generic name

Enbrel(Etanercept)

English name

Etanercept

Alternative Names

Enbrel

Drug prices

Indications

Enbrel is indicated for:

Adults:

Moderately to severely active rheumatoid arthritis (RA) (as monotherapy or combined with methotrexate).

Psoriatic arthritis (PsA).

Ankylosing spondylitis (AS).

Chronic moderate to severe plaque psoriasis (PsO) (candidates for systemic therapy/phototherapy).

Pediatric Patients:

Polyarticular juvenile idiopathic arthritis (pJIA) (≥2 years).

Juvenile psoriatic arthritis (JPsA) (≥2 years).

Plaque psoriasis (PsO) (≥4 years).

Therapeutic Target

Tumor necrosis factor-alpha (TNF-α) and TNF-β (lymphotoxin-alpha).

Active Ingredients

Etanercept

Dosage form

INJECTION

specifications

50 mg/mL (4 syringes)，25 mg/0.5 mL (4 syringes)，50 mg/mL (4 autoinjectors)，25 mg (4 vials)

Description

Etanercept is produced via recombinant DNA technology in Chinese hamster ovary (CHO) cells. The solution is clear, colorless, and preservative-free (except lyophilized powder reconstituted with bacteriostatic water containing 0.9% benzyl alcohol).

Dosage and Administration

Adults:

Condition

Dose & Frequency


RA, PsA, AS	50 mg SC once weekly.
PsO	50 mg SC twice weekly × 3 months, then 50 mg once weekly.

Pediatrics:

Condition

Weight-Based Dosing


pJIA, JPsA, PsO	≥63 kg: 50 mg weekly. <63 kg: 0.8 mg/kg weekly (max 50 mg/week).

Administration Instructions:

Rotate injection sites (thigh, abdomen, upper arm).

Allow prefilled devices to reach room temperature (15–30 minutes).

Do not shake; inspect for particulates/discoloration before use.

CATEGORY NAVIGATION